Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer : A minireview
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme. MMP-9 is one of the most complex forms of matrix metalloproteinases. MMP-9 has the ability to degrade the extracellular matrix (ECM) components and has important role in the pathophysiological functions. Overexpression and dysregulation of MMP-9 is associated with various diseases. Thus, regulation and inhibition of MMP-9 is an important therapeutic approach for combating various diseases including cancer. Inhibitors of MMP-9 can be used as anticancer agents. Till date no selective MMP-9 inhibitors passed the clinical trials. In this review the structure, activation, function and inhibitors of MMP-9 are mainly focused. Some highly active and/or selective MMP-9 inhibitors have been discussed which may be helpful to explore the structural significance of MMP-9 inhibitors. This study may be useful to design new potent and selective MMP-9 inhibitors against cancer in future.
| Errataetall: |
ErratumIn: Eur J Med Chem. 2020 Nov 1;205:112642. - PMID 32750565 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:194 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 194(2020) vom: 15. Mai, Seite 112260 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mondal, Subha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 30.11.2020 Date Revised 30.11.2020 published: Print-Electronic ErratumIn: Eur J Med Chem. 2020 Nov 1;205:112642. - PMID 32750565 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2020.112260 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308100867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308100867 | ||
| 003 | DE-627 | ||
| 005 | 20231225131019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2020.112260 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM308100867 | ||
| 035 | |a (NLM)32224379 | ||
| 035 | |a (PII)S0223-5234(20)30227-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mondal, Subha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer |b A minireview |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2020 | ||
| 500 | |a Date Revised 30.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Eur J Med Chem. 2020 Nov 1;205:112642. - PMID 32750565 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme. MMP-9 is one of the most complex forms of matrix metalloproteinases. MMP-9 has the ability to degrade the extracellular matrix (ECM) components and has important role in the pathophysiological functions. Overexpression and dysregulation of MMP-9 is associated with various diseases. Thus, regulation and inhibition of MMP-9 is an important therapeutic approach for combating various diseases including cancer. Inhibitors of MMP-9 can be used as anticancer agents. Till date no selective MMP-9 inhibitors passed the clinical trials. In this review the structure, activation, function and inhibitors of MMP-9 are mainly focused. Some highly active and/or selective MMP-9 inhibitors have been discussed which may be helpful to explore the structural significance of MMP-9 inhibitors. This study may be useful to design new potent and selective MMP-9 inhibitors against cancer in future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Hydroxamate | |
| 650 | 4 | |a MMP-9 | |
| 650 | 4 | |a MMP-9 inhibitor | |
| 650 | 4 | |a Matrix metalloproteinase | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase Inhibitors |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.35 |2 NLM | |
| 700 | 1 | |a Adhikari, Nilanjan |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Suvankar |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Sk Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Tarun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 194(2020) vom: 15. Mai, Seite 112260 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:194 |g year:2020 |g day:15 |g month:05 |g pages:112260 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2020.112260 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 194 |j 2020 |b 15 |c 05 |h 112260 | ||